Gallic Acid as a Non-Selective Inhibitor of α/β-Hydrolase Fold Enzymes Involved in the Inflammatory Process: The Two Sides of the Same Coin

(1) Background: Gallic acid (GA) has been characterized as an effective anti-inflammatory, antivenom, and promising drug for therapeutic use. (2/3) Methods and Results: GA was identified from ethanolic extract of fresh pitanga (<i>Eugenia uniflora</i>) leaves, which was identified using...

Full description

Saved in:
Bibliographic Details
Main Authors: Marcos Hikari Toyama (Author), Airam Rogero (Author), Laila Lucyane Ferreira de Moraes (Author), Gustavo Antônio Fernandes (Author), Caroline Ramos da Cruz Costa (Author), Mariana Novo Belchor (Author), Agatha Manzi De Carli (Author), Marcos Antônio de Oliveira (Author)
Format: Book
Published: MDPI AG, 2022-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_cb895ccde8574c63b3ee7f1c01dbe4a7
042 |a dc 
100 1 0 |a Marcos Hikari Toyama  |e author 
700 1 0 |a Airam Rogero  |e author 
700 1 0 |a Laila Lucyane Ferreira de Moraes  |e author 
700 1 0 |a Gustavo Antônio Fernandes  |e author 
700 1 0 |a Caroline Ramos da Cruz Costa  |e author 
700 1 0 |a Mariana Novo Belchor  |e author 
700 1 0 |a Agatha Manzi De Carli  |e author 
700 1 0 |a Marcos Antônio de Oliveira  |e author 
245 0 0 |a Gallic Acid as a Non-Selective Inhibitor of α/β-Hydrolase Fold Enzymes Involved in the Inflammatory Process: The Two Sides of the Same Coin 
260 |b MDPI AG,   |c 2022-02-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics14020368 
500 |a 1999-4923 
520 |a (1) Background: Gallic acid (GA) has been characterized as an effective anti-inflammatory, antivenom, and promising drug for therapeutic use. (2/3) Methods and Results: GA was identified from ethanolic extract of fresh pitanga (<i>Eugenia uniflora</i>) leaves, which was identified using commercial GA. Commercial GA neutralized the enzymatic activity of secretory PLA2 (sPLA2) by inhibiting the active site and inducing changes in the secondary structure of the enzyme. Pharmacological edema assays showed that GA strongly decreased edema when the compound was previously incubated with sPLA2. However, prior treatment of GA (30 min before) significantly increased the edema and myotoxicity induced by sPLA2. The molecular docking results of GA with platelet-acetylhydrolase (PAF-AH) and acetylcholinesterase reveal that this compound was able to interact with the active site of both molecules, inhibiting the hydrolysis of platelet-activating factor (PAF) and acetylcholine (ACh). (4) Conclusion: GA has a great potential application; however, our results show that this compound can also induce adverse effects in previously treated animals. Additionally, the increased edema and myotoxicity observed experimentally in GA-treated animals may be due to the inhibition of PAF-AH and Acetylcholinesterase. 
546 |a EN 
690 |a gallic acid 
690 |a edema 
690 |a myotoxic effect 
690 |a snake venom 
690 |a phospholipase A2 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 14, Iss 2, p 368 (2022) 
787 0 |n https://www.mdpi.com/1999-4923/14/2/368 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/cb895ccde8574c63b3ee7f1c01dbe4a7  |z Connect to this object online.